Clay Thorp
SlowingNamed in filings at Hatteras Venture PartnersOn the current fund
- Board seats filed
- 10
- Named on a board
all filings on record
Named in filings at Hatteras Venture PartnersOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Hatteras CREATE SF SPV | Not yet classified | March 2026 | None on file |
| Vigil Neuroscience | Biotech & pharma | September 2020 | Atlas Venture, Vida Ventures |
| PIPr Therapeutics | Not yet classified | March 2019 | None on file |
| StrideBio | Not yet classified | June 2018 | None on file |
| PhaseBio Pharmaceuticals | Not yet classified | February 2015 | None on file |
| ORIG3N | Not yet classified | February 2015 | None on file |
| Lysosomal Therapeutics | Biotech & pharma | January 2015 | Atlas Venture |
| G1 Therapeutics | Not yet classified | October 2013 | None on file |
| GeneCentric Diagnostics | Not yet classified | June 2013 | None on file |
| Clearside Biomedical | Not yet classified | January 2012 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Too few filings to infer a focus. 2 of 10 filed seats classified so far.